伊马替尼（STI571）对转移性胃肠道间质瘤的疗效：一例报告。

Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.

作者信息

Ando Yuichi, Tsunoda Takuya, Beck Yoshifumi, Takayama Takuya, Tahara Hideaki

机构信息

Department of Surgery and Bioengineering, Institute of Medical Science, University of Tokyo, 4-6-1 Minato-ku, Tokyo 108-8639, Japan.

出版信息

Surg Today. 2005;35(2):157-60. doi: 10.1007/s00595-004-2890-6.

DOI:10.1007/s00595-004-2890-6

PMID:15674500

Abstract

The prognosis for advanced gastrointestinal stromal tumor (GIST) is poor. However, recent reports from Europe have described the effects of imatinib against metastatic GIST. We herein report the case of a Japanese patient treated with imatinib for advanced GIST. Imatinib at 400 mg daily was given to an adult with multiple liver and peritoneal metastases 17 months after undergoing a GIST resection. The sum of the diameter of all target lesions decreased from 37.7 to 10.9 cm at 6 months. Tinnitus (grade 2), which has not been reported elsewhere as an adverse effect, developed at 2 months. However, it did not require any treatment. Other adverse effects, nausea (grade 2) and anemia (grade 2), resolved spontaneously. Our results are consistent with previous reports that show imatinib to be effective for the treatment of metastatic GIST, and also suggest that imatinib at 400 mg daily for more than 7 months is well tolerated in Japanese adults.

摘要

晚期胃肠道间质瘤（GIST）的预后较差。然而，欧洲最近的报告描述了伊马替尼对转移性GIST的疗效。我们在此报告1例接受伊马替尼治疗的晚期GIST日本患者。1名成年患者在接受GIST切除术后17个月出现多发肝转移和腹膜转移，给予其每日400 mg伊马替尼治疗。6个月时，所有靶病灶直径总和从37.7 cm降至10.9 cm。2个月时出现耳鸣（2级），这在其他地方尚未作为不良反应报道过。然而，无需任何治疗。其他不良反应，恶心（2级）和贫血（2级），自行缓解。我们的结果与之前显示伊马替尼对转移性GIST治疗有效的报告一致，并且还表明，日本成年人每日服用400 mg伊马替尼超过7个月耐受性良好。